Evaluation of Bronchiectasis Empowerment Tool (BET)

A randomised, investigator-blind controlled trial of the effectiveness and costs of the bronchiectasis empowerment tool in patients with bronchiectasis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN18400127

Enrollment

220

Registered

2015-06-24

Start date

2013-05-03

Completion date

Unknown

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topic: Primary Care, Respiratory disorders

Interventions

Participants are randomly assigned to one of two groups: 1. Bronchiectasis empowerment tool (BET): This consists of a one-page action plan, educational support documents and optional notepads for pati

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Male or female, aged more than 18 years 2. High Resolution Computed tomography (HRCT) diagnosis of bronchiectasis 3. At least one exacerbation of bronchiectasis within the previous 12 months Target Gender: Male & Female ; Lower Age Limit 18 years

Exclusion criteria

Exclusion criteria: 1. Cystic fibrosis related bronchiectasis or traction bronchiectasis 2. Severe or uncontrolled co-morbid disease, which is likely to affect the outcome of the study 3. Abnormalities in cognitive functioning that would limit the patient’s ability to undertake the procedures 4. Currently using a written patient self-management plan or involved in the design of BET 5. Unable to provide written informed consent

Design outcomes

Primary

Measure	Time frame
Self Efficacy; Timepoint(s): By questionnaire at baseline and then every 3 months for a 12 mth period, 5 time points in total.	—

Secondary

Measure	Time frame
1. Change from baseline in health related quality of life measured using the St Georges Respiratory Questionnaire 2. Changes in disease understanding assessed using the Lung Information Needs Questionnaire (LINQ) and non validated questionnaire 3. Difference in the number of exacerbations treated with appropriate antibiotic therapy targeted against sputum bacterial sensitivities during the study obtained from microbiology sensitivity data and prescription data from questionnaires and medication packet inserts returned 4. Difference in the number of unscheduled, emergency or out of hours healthcare contacts for bronchiectasis over the 12 month duration of the study 5. Difference in number and type of all routine and emergency NHS contacts over the 12 month duration of the study 6. Incremental Quality Adjusted Life Years (QALYs) accrued (estimated from EQ-5D data[16]) from baseline 7. A qualitative evaluation of BET from a patient and health care professional point of view	—

Measure

Time frame

1. Change from baseline in health related quality of life measured using the St Georges Respiratory Questionnaire 2. Changes in disease understanding assessed using the Lung Information Needs Questionnaire (LINQ) and non validated questionnaire 3. Difference in the number of exacerbations treated with appropriate antibiotic therapy targeted against sputum bacterial sensitivities during the study obtained from microbiology sensitivity data and prescription data from questionnaires and medication packet inserts returned 4. Difference in the number of unscheduled, emergency or out of hours healthcare contacts for bronchiectasis over the 12 month duration of the study 5. Difference in number and type of all routine and emergency NHS contacts over the 12 month duration of the study 6. Incremental Quality Adjusted Life Years (QALYs) accrued (estimated from EQ-5D data[16]) from baseline 7. A qualitative evaluation of BET from a patient and health care professional point of view

—

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026